Современные подходы к управлению факторами сердечно- сосудистого риска у больных сахарным диабетом 2-го типа
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: сахарный диабет 2-го типа, сердечно-сосудистые заболевания, факторы риска, лечение.
________________________________________________
Diabetes mellitus (DM) type 2 is the serious progressing chronic disease representing independent risk factor of development of cardiovascular complications. The mortality from cardiovascular diseases at the persons suffering from DM type 2 continues to grow around the world, despite constant augmentation of expenses on treatment and prophylaxis. In this article factors of cardiovascular risk at DM are analyzed and possible ways of their correction are surveyed.
Key words: diabetes mellitus type 2, cardiovascular diseases, risk factors, treatment.
2. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-112 [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharnyi Diabet. 2016;19(2):104-112 (In Russ.)]. doi: 10.14341/DM2004116-17
3. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-172.
doi: 10.2337/dc07-0463
4. Аметов А.С., Курочкин И.О., Зубков А.А. Сахарный диабет и сердечно-сосудистые заболевания. Русский медицинский журнал. 2014;22(13):943-958 [Ametov AS, Kurochkin IO, Zubkov AA. Diabetes mellitus and cardiovascular diseases. Russkiy Meditsinskiy Zhurnal. 2014;22(13):943-958 (In Russ.)].
5. Patel A, MacMahon S, Chalmers J; ADVANCE Collaborative Group 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
doi: 10.1056/nejmoa0802987
6. Nalysnyk L, HernandezMedina М, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288-298. doi: 10.1111/j.1463-1326.2009.01160.x
7. Аметов А.С., Богданова Л.Н. Гипергликемия и глюкозотоксичность – ключевые факторы прогрессирования сахарного диабета 2-го типа. Русский медицинский журнал. 2010;18(23):1416-1418 [Ametov AS, Bogdanova LN. Hyperglycemia and glucose toxicity are key factors in the progression of type 2 diabetes mellitus. Russkiy Meditsinskiy Zhurnal. 2010;18(23):1416-1418 (In Russ.)].
8. Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества гликемического контроля и риска осложнений. Сахарный диабет. 2014;17(2):76-82 [Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Sakharnyi Diabet. 2014;17(2):76-82 (In Russ.)]. doi: 10.14341/DM20142
9. Аметов А.С., Абаева Ф.Т. Влияние вариабельности гликемии на течение сахарного диабета 2 типа и современные возможности ее коррекции. Эффективная фармакотерапия. 2012;47:20-25 [Ametov AS, Abaeva FT. Influence of variability of glycemia on the course of type 2 diabetes mellitus and modern possibilities for its correction. Effektivnaya Farmakoterapiya. 2012;47:20-25 (In Russ)].
10. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54(1):1-7. doi: 10.2337/diabetes.54.1.1
11. Hayward RA, Reaven PD, Wiitala WL. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197-2206. doi: 10.1056/NEJMoa1414266
12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014;38:140-149. doi: 10.2337/dc14-2441
13. Currie CJ, Peters JR, Tynan A. Survival as a function of HBA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;357:481-489. doi: 10.1016/s0140-6736(09)61969-3
14. Zoungas S, Patel A, Chalmers J. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-1418. doi: 10.1056/nejmoa1003795
15. Квиткова Л.В., Еленская Т.С., Благовещенская О.П., Зинчук С.Ф., Зинчук И.Г., Барбараш О.Л. Влияние инсулинорезистентности и нарушений углеводного обмена на течение острого периода инфаркта миокарда. Проблемы эндокринологии. 2011;(2):9-13 [Kvitkova LV, Elenskaia TS, Blagoveshchenskaia OP, Zinchuk SF, Zinchuk VG, Barbarash OL. The influence of insulin resistance and disturbances of carbohydrate metabolism in the acute period of myocardial infarction. Problemy Endokrinologii. 2011;(2):9-13 (In Russ)]. doi: 10.14341/probl20115729-13
16. Крюков Н.Н., Титова Ю.Ф., Киселева Г.И., Губарева И.В. Инсулинорезистентность у пациентов с артериальной гипертензией в зависимости от риска сердечно-сосудистых осложнений. Артериальная гипертензия. 2015;21(4):378-385 [Kryukov NN, Titova YuF, Kiseleva GI, Gubareva IV. Insulin resistance in hypertensive patients depending on cardiovascular risk. Arterial’naya Gipertenziya. 2015;21(4):378-385 (In Russ.)]. doi: 10.18705/1607-419x-2015-21-4-378-385
17. Аметов А.С., Прудникова М.А. Ожирение и сахарный диабет типа 2: современные аспекты фармакотерапии. Эндокринология: новости, мнения, обучение. 2016;(4):15-21 [Ametov AS, Prudnikova MA. Obesity and type 2 diabetes: modern aspects of pharmacotherapy. Endokrinologiya: Novosti, Mneniya, Obuchenie. 2016;(4):15-21 (In Russ.)].
18. Аметов А.С., Абдулкадирова Ф.Р., Черникова Н.А., Покровская Р.А., Алферова О.Ю. Роль липотоксичности в достижении гликемического контроля у больных сахарным диабетом 2 типа и ожирением.
Медицинский совет. 2013;(6):84-91 [Ametov АS, Chernikova NA,
Abdulkadirova FR, Pokrovskaya RA, Alferova OYu. Role of lipotoxicity in achieving glycemic control in patients with diabetes type
2 and obesity. Meditsinskii Sovet. 2013;(6):84-91 (In Russ.)].
19. Аметов А.С., Прудникова М.А. Роль препаратов для снижения массы тела в поэтапном управлении сахарным диабетом типа 2: фокус на сибутрамин. Эндокринология: новости, мнения, обучение. 2017;(1):52-59 [Ametov AS, Prudnikova MA. The role of drugs for weight reduction in stages management of type 2 diabetes: focus on sibutramine. Endokrinologiya: Novosti, Mneniya, Obuchenie. 2017;(1):52-59 (In Russ.)].
20. Журавлева А.В., Сокольникова Н.В. Связь резистина, прововоспалительных интерлейкинов и показателей диастолической функции у больных кардиопатией различного генеза. Сибирский медицинский журнал. 2013;28(2):32-35 [Zhuravlyova LV, Sokolnikova NV. Relationship of resistin, proinflammatory interleukines and diastolic dysfunction in patients with cardiomyopathies of different genesis. Sibirskii Meditsinskii Zhurnal. 2013;28(2):32-35 (In Russ.)].
21. Морковских Н.В. Адипонектин и С-реактивный белок как факторы сердечно-сосудистого риска у мужчин с сахарным диабетом
2-го типа. Фарматека. 2010;(8):74-77 [Morkovskikh NV. Adiponectin and C-reactive protein as factors of cardiovascular risk in men with type
2 diabetes mellitus. Farmateka. 2010;(8):74-77 (In Russ.)].
22. Вербовой А.Ф., Осина А.С. Взаимосвязь адипонектина, эндотелина и инсулинорезистентности у больных ожирением и сахарным диабетом 2 типа. Ожирение и метаболизм. 2010;7(2):45-48 [Verbovoy AF, Osina AS. Interrelation of adiponectin, endothelin and insulin resistance in obese patients and type 2 diabetes mellitus. Ozhirenie i Metabolizm. 2010;7(2):45-48 (In Russ.)]. doi: 10.14341/ 071-8713-5208
23. Odden MC, Amadu AR, Smit E. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis. 2014;64(4):550-557. doi: 10.1053/j.ajkd.2014.04.024
24. Матвиевская Е.Н. Распространенность гиперурикемии и ее связь с факторами риска сердечно-сосудистых заболеваний у больных артериальной гипертонией, проживающих в сельской местности. Врач-аспирант. 2017;81(2):43-48 [Matviyevskaya EN. Hyperuricemia incidence and association with cardiovascular disease risk factors in hypertensive patients in a rural area. Vrach-aspirant. 2017;81(2):43-48 (In Russ.)].
25. Мадянов И.В. Мочевая кислота и сахарный диабет. Промежуточные итоги многолетних исследований. Здравоохранение Чувашии. 2017;2(51):59-64 [Madyanov IV. Urolithic acid and sugar diabetes. interim results of multi-year research. Zdravookhranenie Chuvashii. 2017;2(51):59-64 (In Russ.)].
26. Tancredi M, Rosengren A, Svensson AM, Kosiborod M. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373:1720-1732. doi: 10.1056/NEJMoa1504347
27. Иванов К.П., Мычка В.Б., Масенко В.П. Влияние метформина на множественные факторы сердечно-сосудистого риска. Эффективная фармакотерапия. 2012;33:4-8 [Ivanov KP, Mychka VB, Masenko VP. Effect of metformin on multiple factors of cardiovascular risk. Effektivnaya Farmakoterapiya. 2012;33:4-8 (In Russ.)].
28. Chang CH, Chang YC, Lin JW. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study. J Clin Endocrinol Metab. 2015;33:1121-1129. doi: 10.1210/jc.2014-2443
29. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B. Fifty two-week efficacy and saffety of vildagliptinvs.glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabet Obes Metab. 2009;11:157-166. doi: 10.1111/j.1463-1326.2008.00994.x
30. Buse JB, Rosenstock J, Sesti G. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47. doi: 10.1016/s0140-6736(09)60659-0
31. Rosenstock J, Baron MA, Dejager S. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217-223. doi: 10.2337/dc06-1815
32. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147-158. doi: 10.1111/1755-5922.12075
33. He YL, Foteinos G, Neelakantham S, Mattapalli D, Kulmatycki K, Forst T. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes Obes Metab. 2013;15(12):1111-1119. doi: 10.1111/dom.12146
34. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes. Role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076-2082. doi: 10.2337/dc12-0199
35. Аметов А.С., Доскина Е.В., Абаева М.Ш., Нажмутдинова П.К. Ожирение, фактор ухудшающий прогноз и качество жизни пациентов с сахарным диабетом 2 типа. Медико-социальная экспертиза и реабилитация. 2014;(3):48-52 [Ametov AS, Doskina EV, Abaeva MSh, Nazhmutdinova PK. Obesity – a factor that worsens the prognosis and quality of life in patients with type 2 diabetes. Mediko-Sotsial’naya Ekspertiza i Reabilitatsiya. 2014;(3):48-52 (In Russ.)].
36. Аметов А.С., Гусенбекова Д.Г. Роль ингибиторов ДПП-4 в коррекции нарушений жирового обмена у пациентов с СД 2 типа и ожирением. Сахарный диабет. 2015;(3):85-92 [Ametov AS, Gusenbekova DG. The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity. Sakharnyi Diabet. 2015;(3):85-92 (In Russ.)]. doi: 10.14341/dm2015385-92
37. Бабенко А.Ю., Красильникова Е.И., Лихоносов Н.П., Лихоносова А.П., Гринева Е.Н. Влияние различных групп сахароснижающих препаратов на вариабельность гликемии у больных сахарным диабетом 2 типа. Сахарный диабет. 2014;(4):72-80 [Babenko AYu, Krasilnikova EI, Likhonosov NP, Likhonosova AP, Grineva EN. Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients. Sakharnyi Diabet. 2014;(4):72-80 (In Russ.)].
doi: 10.14341/dm2014472-80
38. Аметов А.С., Камынина Л.Л., Ахмедова З.Г. Кардиопротективные эффекты агонистов рецепторов глюкагоноподобного пептида-1. Кардиология. 2014;(7):92-96 [Ametov AS, Kamynina LL, Akhmedova ZG. Cardioprotective effects of glucagon-like peptide 1 receptor agonists. Kardiologiya. 2014;(7):92-96 (In Russ.)]. doi: 10.18565/ cardio.2014.7.92-96
39. Аметов А.С., Камынина Л.Л., Литвиненко В.М. Сердечно-сосудистые эффекты ингибиторов SGLT2 у пациентов с сахарным диабетом типа 2 в реальной клинической практике: исследование CVD-REAL. Эндокринология: новости, мнения, обучение. 2017;(2):28-36 [Ametov AS, Kamynina LL, Litvinenko VM. The cardiovascular effectes of the SGLT2 inhibitors at the patients with type 2 diabetes mellitus in the real-life clinical practice: CVD-REAL trial. Endokrinologiya: Novosti, Mneniya, Obuchenie. 2017;(2):28-36 (In Russ.)].
40. Шестакова М.В., Сухарева О.Ю. Глифлозины: особенности саха-роснижающего действия и негликемические эффекты нового класса препаратов. Клиническая фармакология и терапия. 2016;25(2):65-71 [Shestakova MV, Sukhareva OYu. Gliflozins: glucose-lowering and nonglycemic effects of new class of antidiabetic medications. Klinicheskaya Farmakologiya i Terapiya. 2016;25(2):65-71 (In Russ.)].
41. Салухов В.В., Демидова Т.Ю. Эмпаглифлозин как новая стратегия управления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016;19(6):494-510 [Salukhov VV, Demidova TYu. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus. Sakharnyi Diabet. 2016;19(6):494-510 (In Russ.)].
doi: 10.14341/DM8216
42. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;17(14):142. doi: 10.1186/s12933-015-0297-x
43. Li FF, Gao G, Li Q. Influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus. J Diabetes Res. 2016;2016:5347262.
________________________________________________
1. [Standards of specialized diabetes care]. 8th ed. Moscow: UP PRINT; 2017 (In Russ.)].
2. [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharnyi Diabet. 2016;19(2):104-112 (In Russ.)]. doi: 10.14341/DM2004116-17
3. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-172.
doi: 10.2337/dc07-0463
4. [Ametov AS, Kurochkin IO, Zubkov AA. Diabetes mellitus and cardiovascular diseases. Russkiy Meditsinskiy Zhurnal. 2014;22(13):943-958 (In Russ.)].
5. Patel A, MacMahon S, Chalmers J; ADVANCE Collaborative Group 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
doi: 10.1056/nejmoa0802987
6. Nalysnyk L, HernandezMedina М, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288-298. doi: 10.1111/j.1463-1326.2009.01160.x
7. [Ametov AS, Bogdanova LN. Hyperglycemia and glucose toxicity are key factors in the progression of type 2 diabetes mellitus. Russkiy Meditsinskiy Zhurnal. 2010;18(23):1416-1418 (In Russ.)].
8. [Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Sakharnyi Diabet. 2014;17(2):76-82 (In Russ.)]. doi: 10.14341/DM20142
9. [Ametov AS, Abaeva FT. Influence of variability of glycemia on the course of type 2 diabetes mellitus and modern possibilities for its correction. Effektivnaya Farmakoterapiya. 2012;47:20-25 (In Russ)].
10. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54(1):1-7. doi: 10.2337/diabetes.54.1.1
11. Hayward RA, Reaven PD, Wiitala WL. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197-2206. doi: 10.1056/NEJMoa1414266
12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014;38:140-149. doi: 10.2337/dc14-2441
13. Currie CJ, Peters JR, Tynan A. Survival as a function of HBA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;357:481-489. doi: 10.1016/s0140-6736(09)61969-3
14. Zoungas S, Patel A, Chalmers J. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-1418. doi: 10.1056/nejmoa1003795
15. [Kvitkova LV, Elenskaia TS, Blagoveshchenskaia OP, Zinchuk SF, Zinchuk VG, Barbarash OL. The influence of insulin resistance and disturbances of carbohydrate metabolism in the acute period of myocardial infarction. Problemy Endokrinologii. 2011;(2):9-13 (In Russ)]. doi: 10.14341/probl20115729-13
16. [Kryukov NN, Titova YuF, Kiseleva GI, Gubareva IV. Insulin resistance in hypertensive patients depending on cardiovascular risk. Arterial’naya Gipertenziya. 2015;21(4):378-385 (In Russ.)]. doi: 10.18705/1607-419x-2015-21-4-378-385
17. [Ametov AS, Prudnikova MA. Obesity and type 2 diabetes: modern aspects of pharmacotherapy. Endokrinologiya: Novosti, Mneniya, Obuchenie. 2016;(4):15-21 (In Russ.)].
18. [Ametov АS, Chernikova NA, Abdulkadirova FR, Pokrovskaya RA, Alferova OYu. Role of lipotoxicity in achieving glycemic control in patients with diabetes type 2 and obesity. Meditsinskii Sovet. 2013;(6):84-91 (In Russ.)].
19. [Ametov AS, Prudnikova MA. The role of drugs for weight reduction in stages management of type 2 diabetes: focus on sibutramine. Endokrinologiya: Novosti, Mneniya, Obuchenie. 2017;(1):52-59 (In Russ.)].
20. [Zhuravlyova LV, Sokolnikova NV. Relationship of resistin, proinflammatory interleukines and diastolic dysfunction in patients with cardiomyopathies of different genesis. Sibirskii Meditsinskii Zhurnal. 2013;28(2):32-35 (In Russ.)].
21. [Morkovskikh NV. Adiponectin and C-reactive protein as factors of cardiovascular risk in men with type 2 diabetes mellitus. Farmateka. 2010;(8):74-77 (In Russ.)].
22. [Verbovoy AF, Osina AS. Interrelation of adiponectin, endothelin and insulin resistance in obese patients and type 2 diabetes mellitus. Ozhirenie i Metabolizm. 2010;7(2):45-48 (In Russ.)]. doi: 10.14341/ 071-8713-5208
23. Odden MC, Amadu AR, Smit E. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis. 2014;64(4):550-557. doi: 10.1053/j.ajkd.2014.04.024
24. [Matviyevskaya EN. Hyperuricemia incidence and association with cardiovascular disease risk factors in hypertensive patients in a rural area. Vrach-aspirant. 2017;81(2):43-48 (In Russ.)].
25. [Madyanov IV. Urolithic acid and sugar diabetes. interim results of multi-year research. Zdravookhranenie Chuvashii. 2017;2(51):59-64 (In Russ.)].
26. Tancredi M, Rosengren A, Svensson AM, Kosiborod M. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373:1720-1732. doi: 10.1056/NEJMoa1504347
27. [Ivanov KP, Mychka VB, Masenko VP. Effect of metformin on multiple factors of cardiovascular risk. Effektivnaya Farmakoterapiya. 2012;33:4-8 (In Russ.)].
28. Chang CH, Chang YC, Lin JW. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study. J Clin Endocrinol Metab. 2015;33:1121-1129. doi: 10.1210/jc.2014-2443
29. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B. Fifty two-week efficacy and saffety of vildagliptinvs.glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabet Obes Metab. 2009;11:157-166. doi: 10.1111/j.1463-1326.2008.00994.x
30. Buse JB, Rosenstock J, Sesti G. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47. doi: 10.1016/s0140-6736(09)60659-0
31. Rosenstock J, Baron MA, Dejager S. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217-223. doi: 10.2337/dc06-1815
32. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147-158. doi: 10.1111/1755-5922.12075
33. He YL, Foteinos G, Neelakantham S, Mattapalli D, Kulmatycki K, Forst T. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes Obes Metab. 2013;15(12):1111-1119. doi: 10.1111/dom.12146
34. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes. Role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076-2082. doi: 10.2337/dc12-0199
35. [Ametov AS, Doskina EV, Abaeva MSh, Nazhmutdinova PK. Obesity – a factor that worsens the prognosis and quality of life in patients with type 2 diabetes. Mediko-Sotsial’naya Ekspertiza i Reabilitatsiya. 2014;(3):48-52 (In Russ.)].
36. [Ametov AS, Gusenbekova DG. The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity. Sakharnyi Diabet. 2015;(3):85-92 (In Russ.)]. doi: 10.14341/dm2015385-92
37. [Babenko AYu, Krasilnikova EI, Likhonosov NP, Likhonosova AP, Grineva EN. Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients. Sakharnyi Diabet. 2014;(4):72-80 (In Russ.)].
doi: 10.14341/dm2014472-80
38. [Ametov AS, Kamynina LL, Akhmedova ZG. Cardioprotective effects of glucagon-like peptide 1 receptor agonists. Kardiologiya. 2014;(7):92-96 (In Russ.)]. doi: 10.18565/ cardio.2014.7.92-96
39. [Ametov AS, Kamynina LL, Litvinenko VM. The cardiovascular effectes of the SGLT2 inhibitors at the patients with type 2 diabetes mellitus in the real-life clinical practice: CVD-REAL trial. Endokrinologiya: Novosti, Mneniya, Obuchenie. 2017;(2):28-36 (In Russ.)].
40. [Shestakova MV, Sukhareva OYu. Gliflozins: glucose-lowering and nonglycemic effects of new class of antidiabetic medications. Klinicheskaya Farmakologiya i Terapiya. 2016;25(2):65-71 (In Russ.)].
41. [Salukhov VV, Demidova TYu. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus. Sakharnyi Diabet. 2016;19(6):494-510 (In Russ.)]. doi: 10.14341/DM8216
42. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;17(14):142. doi: 10.1186/s12933-015-0297-x
43. Li FF, Gao G, Li Q. Influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus. J Diabetes Res. 2016;2016:5347262.
1 ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, Самара, Россия;
2 ГАУ ДПО «Институт усовершенствования врачей» Минздрава Чувашии, Чебоксары, Россия
________________________________________________
A.F. Verbovoy 1, A.V. Pashentseva 1, N.I. Verbovaya 1, I.V. Madyanov 2, L.A. Sharonova , R.A. Galkin 3
1 Samara State Medical University, Ministry of Health of Russia, Samara, Russia;
2 Postgraduate Doctors’ Training Institute of Health Care Ministry of Chuvashia, Cheboksary, Russia